CGON Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

72.56K

+68.74%

-0.614

+27.96%

515.18K

+12.98%

-0.668

+48.4%

0.00

-100%

-0.701

+29.84%

Estimates Revision

The market is revising Upward the revenue expectations for CG Oncology, Inc. (CGON) for FY2025, with the revenue forecasts being adjusted by 94.51% over the past three months. During the same period, the stock price has changed by 3.00%.

Revenue Estimates for FY2025

Revise Upward

+94.51%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.24%

In Past 3 Month

Stock Price

Go Up

+3.00%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast CGON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGON is 70.09 USD with a low forecast of 55.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

55.00

Averages

70.09

High

90.00

Current: 0.000

Low

55.00

Averages

70.09

High

90.00

Wedbush

Outperform

initiated

$70

2025-12-11

Reason

Wedbush

Price Target

$70

2025-12-11

initiated

Outperform

Reason

Wedbush initiated coverage of CG Oncology with an Outperform rating and $70 price target. The firm notes the company is developing an oncolytic virus, cretostimogene grenadenorepvec, for the treatment of NMIBC. Wedbush believes cretostimogene's mechanisms of action, including selective killing of tumor cells, and triggering of an anti-tumor immune response are critical to driving robust efficacy across high-risk BCG-unresponsive non-muscle invasive bladder cancer settings. Furthermore, the firm thinks cretostimogene's favorable safety/tolerability profile and intravesical administration will allow for broad uptake in a large commercial market as a differentiated treatment option. Wedbush looks forward to completion of a BLA submission in 2026, as well as meaningful clinical readouts that it expects to drive shares higher, ahead of a potential commercial launch.

Truist

Gregory Renza

Buy

initiated

$62

2025-11-24

Reason

Truist

Gregory Renza

Price Target

$62

2025-11-24

initiated

Buy

Reason

Truist analyst Gregory Renza initiated coverage of CG Oncology with a Buy rating and $62 price target. The firm views Creto's high complete response rates, favorable tolerability, and differentiated durability as key attributes that could support robust market positioning for the company, the analyst tells investors in a research note. The potential expansion into intermediate-risk/IR NMIBC, or Non-Muscle Invasive Bladder Cancer, and additional high-risk settings represent a strategic approach that could broaden Creto's commercial opportunity, given the ongoing BCG - Bacillus Calmette Guerin - shortage, Truist added.

RBC Capital

Outperform

maintain

$53 -> $61

2025-11-17

Reason

RBC Capital

Price Target

$53 -> $61

2025-11-17

maintain

Outperform

Reason

RBC Capital raised the firm's price target on CG Oncology to $61 from $53 and keeps an Outperform rating on the shares. CG Oncology's Q3 update highlighted that its BLA filing is now underway, easing concerns about timing and keeping the company on track for a potentially strong non-muscle invasive bladder cancer launch with a more than $2.7B opportunity, the analyst tells investors in a research note. With additional Q4 catalysts ahead and a favorable safety/efficacy profile despite competitive questions, the outlook remains compelling, RBC says.

BofA

Buy

downgrade

$62 -> $60

2025-11-14

Reason

BofA

Price Target

$62 -> $60

2025-11-14

downgrade

Buy

Reason

BofA lowered the firm's price target on CG Oncology to $60 from $62 as the firm pushes back launch timing for creto to 2027 and updates operating expense expectation. BofA keeps a Buy rating on the shares. The firm notes that the company announced in their Q3 print that they have initiated their rolling BLA submission to the FDA for creto in HR BCG-unresponsive NMIBC. BofA continues to see an attractive setup heading into the BLA/potential approval given creto's durability and safety continue to shine.

JPMorgan

NULL -> Overweight

maintain

$41 -> $47

2025-09-26

Reason

JPMorgan

Price Target

$41 -> $47

2025-09-26

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on CG Oncology to $47 from $41 and keeps an Overweight rating on the shares. The firm rolled forward its price target.

Morgan Stanley

Overweight

upgrade

$56 -> $79

2025-09-17

Reason

Morgan Stanley

Price Target

$56 -> $79

2025-09-17

upgrade

Overweight

Reason

Morgan Stanley raised the firm's price target on CG Oncology to $79 from $56 and keeps an Overweight rating on the shares. The approval of Inlexzo and higher-than-expected price bolsters Morgan Stanley's confidence in creto's regulatory pathway ahead as well as peak sales potential, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for CG Oncology Inc (CGON.O) is -15.37, compared to its 5-year average forward P/E of -17.70. For a more detailed relative valuation and DCF analysis to assess CG Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.70

Current PE

-15.37

Overvalued PE

-12.74

Undervalued PE

-22.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.71

Current EV/EBITDA

-11.87

Overvalued EV/EBITDA

-7.20

Undervalued EV/EBITDA

-20.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3361.84

Current PS

4209.06

Overvalued PS

4568.90

Undervalued PS

2154.78

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CGON News & Events

Events Timeline

No data

News

8.0

2025-12-19NASDAQ.COM

Inaugural Week of CGON Options Trading for February 2026

7.5

2025-12-18Newsfilter

CG Oncology Partners with SUO-CTC to Establish $50,000 NMIBC Research Fellowship

4.0

2025-11-27TipRanks

Three Stocks with Significant Growth Potential, According to Top Analysts – 11/27/2025

People Also Watch

Frequently Asked Questions

What is CG Oncology Inc (CGON) stock price today?

The current price of CGON is 41.93 USD — it has decreased -1.22 % in the last trading day.

What is CG Oncology Inc (CGON)'s business?

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

What is the price predicton of CGON Stock?

What is CG Oncology Inc (CGON)'s revenue for the last quarter?

CG Oncology Inc revenue for the last quarter amounts to 1.67M USD, increased 3774.42 % YoY.

What is CG Oncology Inc (CGON)'s earnings per share (EPS) for the last quarter?

CG Oncology Inc. EPS for the last quarter amounts to -0.57 USD, increased 90.00 % YoY.

What changes have occurred in the market's expectations for CG Oncology Inc (CGON)'s fundamentals?

How many employees does CG Oncology Inc (CGON). have?

CG Oncology Inc (CGON) has 113 emplpoyees as of January 08 2026.

What is CG Oncology Inc (CGON) market cap?

Today CGON has the market capitalization of 3.42B USD.